Skip to content
Peptides Codex
ENFR

Use the arrow keys to choose a result, Enter to open it, and Escape to close.

← Home
Ghrelin receptor agonist (peptidomimetic)

Capromorelin

Capromorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist that increases appetite and stimulates growth hormone release.

By The Peptides Codex Editorial TeamIndividual review date not recorded

Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.

Length
n/a
Class
Ghrelin receptor agonist (peptidomimetic)
Function
Growth hormone secretagogue receptor agonist
Context
FDA-approved for veterinary use as an appetite stimulant in dogs and cats; human development was discontinued

A ghrelin-mimetic appetite stimulant approved for companion animals.

Also known as: Entyce · Elura · CP-424391

Part of the Growth hormone & IGF peptides cluster

Overview

Capromorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist that increases appetite and stimulates growth hormone release. It is FDA-approved for veterinary use as an appetite stimulant in dogs and cats; human development was discontinued. This page is educational and is not medical advice.

Source & context

Biological / chemical source: Synthetic orally active peptidomimetic

Primary research or clinical context: FDA-approved for veterinary use as an appetite stimulant in dogs and cats; human development was discontinued

Veterinary appetite stimulant

Marketed as Entyce and Elura, capromorelin is used to address inappetence and weight loss in companion animals. Its ghrelin-receptor activity drives both appetite signaling and downstream growth hormone and IGF-1 effects.

From human trials to animal health

Capromorelin was originally studied in humans, including trials in older adults, before human development was halted. Its path into veterinary medicine is a common story for ghrelin-mimetic secretagogues.

Structure & chemistry

Molecular identity & reference confidence

Source-supported reference

Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.

Molecular form
Capromorelin (source record; form not independently established)
Species
Not established by this molecular identity audit
Termini (N / C)
Not specified / Not specified

Average reference mass

Reference policy updated: 2026-10-05

Molecular formula
C28H35N5O4
Average reference mass
≈ 505.6
Identifiers

Chemistry values: PubChem · fetched 2026-10-01.

Concentration math

Capromorelin — reconstitution calculator

Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.

Reference form: Capromorelin (source record; form not independently established)Average reference mass: 505.6 Da

Syringe graduation
Solution concentration
5 mg/mL5,000 mcg/mL
mcg

Enter an amount to see the volume it corresponds to.

Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.

Open the Capromorelin calculator on its own page →

FAQ about Capromorelin

What is Capromorelin?+

Capromorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist that increases appetite and stimulates growth hormone release. It is FDA-approved for veterinary use as an appetite stimulant in dogs and cats; human development was discontinued. This page is educational and is not medical advice.

What Canadian product status is recorded for Capromorelin?+

Canadian product status for Capromorelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.

What is the typical length of Capromorelin?+

Capromorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

PE-22-28
Research peptide
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Cortexin
Polypeptide complex
Cortexin is a low-molecular-weight polypeptide complex extracted from cerebral cortex tissue, studied largely in Russian neuroscience literature. It is marketed as a drug in some countries but is not authorized by Health Canada.
Pinealon
Research peptide
Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR), one of the Khavinson short-peptide bioregulators. Its evidence is rodent, cell-culture and small uncontrolled Russian human observations reporting antioxidant and neuroprotective effects; no registered clinical trial exists and it is not an approved medicine in the US, Canada or the EU.
Teverelix
GnRH antagonist (decapeptide analog)
Teverelix is a synthetic decapeptide GnRH antagonist that binds competitively and reversibly to pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone. It is an investigational compound studied in prostate disorders and is not authorized by Health Canada. This page is educational and is not medical advice.

References & further reading

  1. 1.Titel et al. (2025). Effects of Capromorelin, Mirtazapine, and Cyproheptadine on Food Intake in Budgerigars (Melopsittacus undulatus). J Avian Med Surg
  2. 2.Ellis et al. (2015). Pharmacokinetics of the ghrelin agonist capromorelin in a single ascending dose Phase-I safety trial in spinal cord-injured and able-bodied volunteers. Spinal Cord
  3. 3.Rhodes et al. (2018). Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs. Vet Med Sci
  4. 4.Pires et al. (2021). The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats. Domest Anim Endocrinol
  5. 5.Carpino et al. (2003). Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin. Bioorg Med Chem
  6. 6.Pascutti et al. (2022). The effect of capromorelin on glycemic control in healthy dogs. Domest Anim Endocrinol
  7. 7.Wofford et al. (2025). Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial. J Feline Med Surg
  8. 8.Campellone et al. (2024). Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (Macaca mulatta). J Am Assoc Lab Anim Sci
  9. 9.PubChem — compound summary for Capromorelin (CID 216208)
  10. 10.Wikipedia — Capromorelin
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Capromorelin educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.